Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says

Executive Summary

Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.

You may also be interested in...



Woodcock Says Blowing Up Orphan Drug Act Not Advisable In Current Climate

FDA appears just as nervous as the National Organization for Rare Disorders about what Congress would do if asked to tweak the Orphan Drug Act.

Woodcock Says Blowing Up Orphan Drug Act Not Advisable In Current Climate

FDA appears just as nervous as the National Organization for Rare Disorders about what Congress would do if asked to tweak the Orphan Drug Act.

PDUFA Commitment Letter Formalizes REMS Standardization Schedule

Among other timetables set as part of the broad deal with industry, FDA will host meetings and issue guidances to assess and minimize the burden of REMS on the practitioners and patients.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel